Is the FDA Too Cautious?
Open to Debate
The Importance of Broadening the Aperture
I think I actually think the industry, the biopharma industry should embrace it. CMS now for the first time is going to be negotiating drug prices. And so what people have been sort of scared about for a long time is coming. We don't want to just be the tallest A.Z. in the bunch. We want to make a whole new field of A.Zs that really changes the world and changes.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
